Pharmacogenomics allows us to identify sources of an individual’s profile of drug response and predict the best possible treatment option for this individual. The use of genomic information has opened new possibilities in drug discovery and development.
The Genomics Group, in FDA's Office of Clinical Pharmacology, works to advance the application of Genomics in the discovery, development, regulation, and use of medication.
Overview of the Genomics Group
- Vision: Advance the application of Genomics for the benefits of patients and society.
- Mission: Recognition of Genomics as an integral discipline in the discovery, development, regulation and rational use of medication (DDRU).
Regulatory and Scientific Information
Table of Pharmacogenomic Biomarkers in Drug Labels Genomics Guidances, Concept Papers, and MaPPs Voluntary Exploratory Data Submissions (VXDS)
[formerly Voluntary Genomic Data Submission (VGDS)]
Genomics: Frequently Asked Questions